CLOVIS ONCOLOGY Forum: Community User: Maroni

sieht auf jeden FALL so aus

Chart. ..Ausbruch oder wie soll ich das verstehen?

https://t.co/NqjTkmASkQ

mal sehen wo die Richtung zum 8.8 hingeht...

Clovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.

KOLs discuss #PARP inhibitor #rucaparib after $CLVS rejigs #LOH cutoff for #non-BRCA ovarian cancer patients

Nein machst du nicht. .hab kurz überflogen aber zZ gaaaanz gaaaanz wenig Zeit gehabt.Ab nächste WOCHE wirds ruhiger!!!Grüsse

Sieht so aus :) Und Infos verbreiten für investierte bzw interessierte Aktionäre

Vanhalen, redest du mit dir selbst?

In diversen Foren wird über ein Buy-Out spekuliert ..... Hmm

Bleibt die Frage, warum er jetzt über 5% hält, und seit wann?

Morgan Stanley owns 1,697,692 shares or 5.2%: 13G filed by Morgan Stanleyhttps://t.co/FDMoNz1mt3,https://t.co/uXklE7bINS

Schlechter Tag.....

@ACInvestorBlog $CLVS CMF is now positive.....buying momentum is starting to rise, a breakout could be possible.https://t.co/JwxWQSVgUO

Kazazian Asset Management LLC purchased a new stake in Clovis Oncology Inc. (NASDAQ:CLVS) during the first quarter, Holdings Channel reports. The fund purchased 14,666 shares of the biopharmaceutical company’s stock, valued at approximately $282,000. Clovis Oncology comprises 0.5% of Kazazian Asset Management LLC’s portfolio, making the stock its 24th largest position. Several other hedge funds have also recently modified their holdings of the company. State Street Corp boosted its stake in shares of Clovis Oncology by 21.2% in the first quarter. State Street Corp now owns 1,797,874 shares of the biopharmaceutical company’s stock valued at $34,525,000 after buying an additional 313,893 shares during the last quarter. Redmile Group LLC boosted its stake in shares of Clovis Oncology by 87.5% in the fourth quarter. Redmile Group LLC now owns 1,795,936 shares of the biopharmaceutical company’s stock valued at $62,858,000 after buying an additional 838,302 shares during the last quarter. HealthCor Management L.P. purchased a new stake in shares of Clovis Oncology during the fourth quarter valued at approximately $53,375,000. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Clovis Oncology by 7.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 825,085 shares of the biopharmaceutical company’s stock valued at $15,842,000 after buying an additional 54,476 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Clovis Oncology during the first quarter valued at approximately $9,896,000. Shares of Clovis Oncology Inc. (NASDAQ:CLVS) traded down 0.07% during midday trading on Monday, hitting $14.72. The stock had a trading volume of 66,652 shares. Clovis Oncology Inc. has a 52 week low of $11.57 and a 52 week high of $116.75. The stock has a 50-day moving average of $14.76 and a 200 day moving average of $18.53. The stock’s market cap is $565.03 million.

http://tinyurl.com/jrexno8